-
Send to Friends (0)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Checklist of Responsibilities for the Scientific Editor of This Article
Publishing Process of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (14723)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jun 14, 2019 (publication date) through Feb 7, 2023
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i22/2706.htm |
| Number | Citing Articles |
| 1 |
Asimina Koulouridi, Ippokratis Messaritakis, Nikolaos Gouvas, John Tsiaoussis, John Souglakos. Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer. Cancers 2020; 13(1): 43 doi: 10.3390/cancers13010043
|
| 2 |
Leon Fisher, Alexander Fisher, Paul N Smith. Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review). Journal of Clinical Medicine 2020; 9(10): 3253 doi: 10.3390/jcm9103253
|
| 3 |
Valentina Fabiano, Flavia Indrio, Elvira Verduci, Valeria Calcaterra, Tudor Lucian Pop, Alessandra Mari, Gian Vincenzo Zuccotti, Fugen Cullu Cokugras, Massimo Pettoello-Mantovani, Olivier Goulet. Term Infant Formulas Influencing Gut Microbiota: An Overview. Nutrients 2021; 13(12): 4200 doi: 10.3390/nu13124200
|
| 4 |
Louis Gaucher, Leslie Adda, Alice Séjourné, Camille Joachim, Chaby Guillaume, Claire Poulet, Sophie Liabeuf, Valérie Gras-Champel, Kamel Masmoudi, Aline Houessinon, Youssef Bennis, Benjamin Batteux. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology 2021; 13: 175883592110005 doi: 10.1177/17588359211000591
|
| 5 |
Octavio Gómez-Escudero. Benign Anorectal Disorders - An Update. 2023; doi: 10.5772/intechopen.103734
|
| 6 |
Alessandro Rizzo, Matteo Santoni, Veronica Mollica, Angela Dalia Ricci, Concetta Calabrò, Antonio Cusmai, Gennaro Gadaleta-Caldarola, Gennaro Palmiotti, Francesco Massari. The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis. Journal of Personalized Medicine 2022; 12(5): 842 doi: 10.3390/jpm12050842
|
| 7 |
Muhammad Miftahussurur, Boby Pratama Putra, Yoshio Yamaoka. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals 2020; 13(10): 276 doi: 10.3390/ph13100276
|
| 8 |
Nele Brusselaers, Marcela Pereira, Johan Alm, Lars Engstrand, Helene Engstrand Lilja. Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort. Gut Pathogens 2022; 14(1) doi: 10.1186/s13099-022-00518-9
|
| 9 |
Yoshiharu Okuyama, Teppei Okamoto, Daichi Sasaki, Kai Ozaki, Jung Songee, Shingo Hatakeyama, Tatsuya Mikami, Chikara Ohyama. The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan. International Urology and Nephrology 2022; 54(1): 9 doi: 10.1007/s11255-021-03044-w
|
| 10 |
Monique R. Bidell, Athena L. V. Hobbs, Thomas P. Lodise. Gut microbiome health and dysbiosis: A clinical primer. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2022; 42(11): 849 doi: 10.1002/phar.2731
|
| 11 |
Narongrit Thongon, Nasisorn Suksridechacin, Siriporn Chamniansawat. Current opinion on the regulation of small intestinal magnesium absorption. World Journal of Gastroenterology 2023; 29(2): 332-342 doi: 10.3748/wjg.v29.i2.332
Abstract(45) |
Core Tip(40) |
Full Article(HTML)(348)
|
Full Article (PDF)-3175K(46)
|
Full Article (Word)-1056K(11)
|
Audio-1524K(0)
|
Peer-Review Report-222K(5)
|
Answering Reviewers-136K(3)
|
Times Cited (0)
|
Total Visits (712)
|
Open
|
| 12 |
Magdalena Dzikowiec, Dorota Pastuszak-Lewandoska. The uninvited guests of our microbiome: Helicobacter pylori and Epstein-Barr virus and their role in gastric cancerogenesis. Postępy Higieny i Medycyny Doświadczalnej 2021; 75(1): 611 doi: 10.2478/ahem-2021-0008
|
| 13 |
Wu Yinhang, Wu Wei, Zhuang Jing, Zhou Qing, Zhou Yani, Wang Yangyanqiu, Han Shuwen. Biological roles of toll-like receptors and gut microbiota in colorectal cancer. Future Microbiology 2022; 17(13): 1071 doi: 10.2217/fmb-2021-0072
|
| 14 |
Irene Gullo, Catarina Costa, Susana L. Silva, Cristina Ferreira, Adriana Motta, Sara P. Silva, Rúben Duarte Ferreira, Pedro Rosmaninho, Emília Faria, José Torres da Costa, Rita Câmara, Gilza Gonçalves, João Santos-Antunes, Carla Oliveira, José C. Machado, Fátima Carneiro, Ana E. Sousa. The Dysfunctional Immune System in Common Variable Immunodeficiency Increases the Susceptibility to Gastric Cancer. Cells 2020; 9(6): 1498 doi: 10.3390/cells9061498
|
| 15 |
Zhi‐Hang Tao, Ji‐Xuan Han, Jing‐Yuan Fang.
Helicobacter pylori
infection and eradication: Exploring their impacts on the gastrointestinal microbiota
. Helicobacter 2020; 25(6) doi: 10.1111/hel.12754
|
| 16 |
Judith Wellens, João Sabino, Séverine Vermeire. PPIs and anti-TNF in patients with IBD: a forbidden combination?. Gut 2021; 70(12): 2397.1 doi: 10.1136/gutjnl-2021-324040
|
| 17 |
Ana Almeida-Santos, Daniela Martins-Mendes, Magdalena Gayà-Vidal, Lucía Pérez-Pardal, Albano Beja-Pereira. Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients. Frontiers in Microbiology 2021; 12 doi: 10.3389/fmicb.2021.610370
|
| 18 |
Claudio Barbiellini Amidei, Rosanna Comoretto, Loris Zanier, Daniele Donà, Anna Cantarutti, Cristina Canova. Acid-suppressive medications in the first year of life and risk of childhood asthma: a population-based birth cohort study. European Respiratory Journal 2020; 56(5): 2000197 doi: 10.1183/13993003.00197-2020
|
| 19 |
Jong Min Park, Won Hee Lee, Hochan Seo, Ji Young Oh, Dong Yoon Lee, Seong Jin Kim, Ki Baik Hahm. Microbiota changes with fermented kimchi contributed to either the amelioration or rejuvenation of <i>Helicobacter pylori</i>-associated chronic atrophic gastritis. Journal of Clinical Biochemistry and Nutrition 2021; 69(1): 98 doi: 10.3164/jcbn.20-123
|
| 20 |
Jianyi Yin, Roy Elias, Lan Peng, Nicholas Levonyak, Annapoorani Asokan, Alana Christie, Nisa Kubiliun, James Brugarolas, Hans J. Hammers. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022; 20(3): 260 doi: 10.1016/j.clgc.2022.01.017
|
| 21 |
Cindy Duysburgh, Lynn Verstrepen, Mattia Van den Broeck, Zefferino Righetto, Marcos Perez. Investigation of Enterogermina’s Protective and Restorative Mechanisms on the Gut Microbiota with PPI, Using SHIME Technology. Nutrients 2023; 15(3): 653 doi: 10.3390/nu15030653
|
| 22 |
Joshua Bilello, Ikenna Okereke. Impact of Environmental and Pharmacologic Changes on the Upper Gastrointestinal Microbiome. Biomedicines 2021; 9(6): 617 doi: 10.3390/biomedicines9060617
|
| 23 |
Nele Brusselaers, Jesper Lagergren, Lars Engstrand. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiology 2019; 62: 101585 doi: 10.1016/j.canep.2019.101585
|
| 24 |
Volker Schirrmacher. Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism. Biomedicines 2020; 8(11): 526 doi: 10.3390/biomedicines8110526
|
| 25 |
Chia-Jung Kuo, Cheng-Yu Lin, Chun-Wei Chen, Chiu-Yi Hsu, Sen-Yung Hsieh, Cheng-Tang Chiu, Wey-Ran Lin. Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study. Journal of Personalized Medicine 2021; 11(11): 1063 doi: 10.3390/jpm11111063
|
| 26 |
I. A. Krylova, V. I. Kupaev, A. V. Ljamin. Microbiological Characteristics of Intestinal Biocenosis of Ambulator Patients Having Behavioral Risk Factors for Chronic Non-Communicable Diseases. The Russian Archives of Internal Medicine 2021; 11(3): 217 doi: 10.20514/2226-6704-2021-11-3-217-224
|
| 27 |
Byung Soo Yoo, Alsiddig Elmahdi, Ana Vilela, Steve M. D’Souza, Kevin V. Houston, David A. Johnson. Esophageal Disease and the Role of the Microbiome. 2023; : 163 doi: 10.1016/B978-0-323-95070-1.00006-0
|
| 28 |
Thomas H. Tranah, Victoria T. Kronsten, Debbie L. Shawcross. Implications and Management of Cirrhosis‐Associated Immune Dysfunction Before and After Liver Transplantation. Liver Transplantation 2022; 28(4): 700 doi: 10.1002/lt.26353
|
| 29 |
Thomas X Lu, Matthew Dapas, Erika Lin, Trevor Peters, Atsushi Sakuraba. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. Gut 2021; 70(11): 2076 doi: 10.1136/gutjnl-2020-321609
|
| 30 |
Nadji Hannachi, Laurence Camoin-Jau. Drug Response Diversity: A Hidden Bacterium?. Journal of Personalized Medicine 2021; 11(5): 345 doi: 10.3390/jpm11050345
|
| 31 |
Meghali Nighot, Pei-Luan Liao, Nathan Morris, Dennis McCarthy, Viszwapriya Dharmaprakash, Inam Ullah Khan, Shannon Dalessio, Kushal Saha, Ashwinkumar Subramaniam Ganapathy, Alexandra Wang, Wei Ding, Gregory Yochum, Walter Koltun, Prashant Nighot, Thomas Ma. Long-Term Use of Proton Pump Inhibitors Disrupts Intestinal Tight Junction Barrier and Exaggerates Experimental Colitis. Journal of Crohn's and Colitis 2022; doi: 10.1093/ecco-jcc/jjac168
|
| 32 |
Enrico Pierluigi Spugnini, Stefano Fais. Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors. Expert Opinion on Therapeutic Patents 2020; 30(1): 15 doi: 10.1080/13543776.2020.1704733
|
| 33 |
Cheng-Yuan Li, Ying-Xiu Dai, Yun-Ting Chang, Ya-Mei Bai, Shih-Jen Tsai, Tzeng-Ji Chen, Mu-Hong Chen. Proton Pump Inhibitors Are Associated with Increased Risk of Psoriasis: A Nationwide Nested Case-Control Study. Dermatology 2021; 237(6): 884 doi: 10.1159/000517515
|
| 34 |
M. Yadav, N.S. Chauhan. Overview of the rules of the microbial engagement in the gut microbiome: a step towards microbiome therapeutics. Journal of Applied Microbiology 2021; 130(5): 1425 doi: 10.1111/jam.14883
|
| 35 |
Luis A. García Rodríguez, Angel Lanas, Montse Soriano-Gabarró, Pareen Vora, Lucía Cea Soriano. Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study. Journal of Clinical Medicine 2020; 9(4): 928 doi: 10.3390/jcm9040928
|
| 36 |
Issac E. Perry, Irene Sonu, Carmelo Scarpignato, Junichi Akiyama, Michio Hongo, Kenneth J. Vega. Potential proton pump inhibitor–related adverse effects. Annals of the New York Academy of Sciences 2020; 1481(1): 43 doi: 10.1111/nyas.14428
|
| 37 |
Aleksandra Danielak, John L Wallace, Tomasz Brzozowski, Marcin Magierowski. Gaseous Mediators as a Key Molecular Targets for the Development of Gastrointestinal-Safe Anti-Inflammatory Pharmacology. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.657457
|
| 38 |
Hüseyin S Bozkurt, Ömer Bilen. Gastrointestinal symptoms in COVID-19 could be associated with severe lung involvement and increased readmission rates. European Journal of Inflammation 2021; 19: 205873922110482 doi: 10.1177/20587392211048259
|
| 39 |
H. B. Isayev, M. R. Ibrahimov, T. H. Salimov. Dependence of the state of the large intestine parietal microflora on the activity of Helicobacter pylori associated chronic gastritis. Ural Medical Journal 2021; 20(3): 44 doi: 10.52420/2071-5943-2021-20-3-44-48
|
| 40 |
Claudio Barbiellini Amidei, Fabiana Zingone, Loris Zanier, Cristina Canova. Risk of Prevalent Asthma among Children Affected by Inflammatory Bowel Disease: A Population-Based Birth Cohort Study. International Journal of Environmental Research and Public Health 2020; 17(12): 4255 doi: 10.3390/ijerph17124255
|
| 41 |
Anna Cantarutti, Claudio Barbiellini Amidei, Camilla Valsecchi, Antonio Scamarcia, Giovanni Corrao, Dario Gregori, Carlo Giaquinto, Jonas Ludvigsson, Cristina Canova. Association of Treated and Untreated Gastroesophageal Reflux Disease in the First Year of Life with the Subsequent Development of Asthma. International Journal of Environmental Research and Public Health 2021; 18(18): 9633 doi: 10.3390/ijerph18189633
|
| 42 |
Wen Hu, Yunhao Luo, Xiujuan Yang. Inappropriate Use of Proton Pump Inhibitors Increases Cardiovascular Events in Patients with Coronary Heart Disease. International Journal of General Medicine 2022; : 8685 doi: 10.2147/IJGM.S392767
|
| 43 |
Tomoko Mizaki, Hironobu Nobata, Shogo Banno, Makoto Yamaguchi, Hiroshi Kinashi, Shiho Iwagaitsu, Takuji Ishimoto, Yukiko Kuru, Masafumi Ohnishi, Ken-ichi Sako, Yasuhiko Ito. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis. Journal of Pharmaceutical Health Care and Sciences 2023; 9(1) doi: 10.1186/s40780-022-00271-w
|
| 44 |
Sébastien Lopes, Lucile Pabst, Anne Dory, Marion Klotz, Bénédicte Gourieux, Bruno Michel, Céline Mascaux. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1070076
|
| 45 |
Pamela A. McCombe, Fleur C Garton, Matthew Katz, Naomi R Wray, Robert D Henderson. What do we know about the variability in survival of patients with amyotrophic lateral sclerosis?. Expert Review of Neurotherapeutics 2020; 20(9): 921 doi: 10.1080/14737175.2020.1785873
|
| 46 |
Manyu Li, Chaofan Zeng, Jiannan Yao, Yang Ge, Guangyu An. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy. International Immunopharmacology 2020; 88: 106972 doi: 10.1016/j.intimp.2020.106972
|
| 47 |
Youssef Bouferraa, Andrea Chedid, Ghid Amhaz, Ahmed El Lakkiss, Deborah Mukherji, Sally Temraz, Ali Shamseddine. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. International Journal of Molecular Sciences 2021; 22(15): 8036 doi: 10.3390/ijms22158036
|
| 48 |
Nadiya Hussain, Muntaha Naeem, David J. Pinato. Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?. Human Vaccines & Immunotherapeutics 2021; 17(1): 55 doi: 10.1080/21645515.2020.1769398
|
| 49 |
Axel Dalhoff. Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?. Infection 2021; 49(4): 569 doi: 10.1007/s15010-020-01547-9
|
| 50 |
Sadia Tasnim, Aaron L. Miller, Daniel C. Jupiter, Catherine F. Hamilton, Gabriel L. Reep, Timothy S. Krill, Richard B. Pyles, Ikenna C. Okereke. Effects of proton pump inhibitor use on the esophageal microbial community. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01460-3
|
| 51 |
Rodney R. Dietert. Microbiome First Medicine in Health and Safety. Biomedicines 2021; 9(9): 1099 doi: 10.3390/biomedicines9091099
|
| 52 |
Lili Yu, Gang Zhao, Lijuan Wang, Xuan Zhou, Jing Sun, Xinxuan Li, Yingshuang Zhu, Yazhou He, Kleovoulos Kofonikolas, Debby Bogaert, Malcolm Dunlop, Yimin Zhu, Evropi Theodoratou, Xue Li. A systematic review of microbial markers for risk prediction of colorectal neoplasia. British Journal of Cancer 2022; 126(9): 1318 doi: 10.1038/s41416-022-01740-7
|
| 53 |
Sho Kitamoto, Nobuhiko Kamada. Untangling the oral–gut axis in the pathogenesis of intestinal inflammation. International Immunology 2022; 34(9): 485 doi: 10.1093/intimm/dxac027
|
| 54 |
Lisanne M. M. Gommers, Joost G. J. Hoenderop, Jeroen H. F. de Baaij. Mechanisms of proton pump inhibitor‐induced hypomagnesemia. Acta Physiologica 2022; 235(4) doi: 10.1111/apha.13846
|
| 55 |
Piera Zaccari, Livia Archibugi, Giulio Belfiori, Enrico Nista, Giuseppe dell'Anna, Stefano Crippa, Tommaso Schepis, Matteo Tacelli, Francesca Aleotti, Maria Chiara Petrone, Alberto Mariani, Guido Costamagna, Antonio Gasbarrini, Alberto Larghi, Massimo Falconi, Paolo Giorgio Arcidiacono, Gabriele Capurso. Risk factors for the occurrence of ampullary tumors: A case‐control study. United European Gastroenterology Journal 2022; 10(7): 730 doi: 10.1002/ueg2.12281
|
| 56 |
Alessio Cortellini, Marco Tucci, Vincenzo Adamo, Luigia Stefania Stucci, Alessandro Russo, Enrica Teresa Tanda, Francesco Spagnolo, Francesca Rastelli, Renato Bisonni, Daniele Santini, Marco Russano, Cecilia Anesi, Raffaele Giusti, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Mario Alberto Occhipinti, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Claudia Bareggi, Olga Nigro, Alessandro Tuzi, Michele De Tursi, Nicola Petragnani, Laura Pala, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Barbara Di Cocco, Domenico Mallardo, Maria Grazia Vitale, David James Pinato, Giampiero Porzio, Corrado Ficorella, Paolo Antonio Ascierto. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. Journal for ImmunoTherapy of Cancer 2020; 8(2): e001361 doi: 10.1136/jitc-2020-001361
|
| 57 |
Larissa Spósito, Giovanna Capaldi Fortunato, Bruna Almeida Furquim de Camargo, Matheus Aparecido dos Santos Ramos, Maurício Palmeira Chaves de Souza, Andréia Bagliotti Meneguin, Taís Maria Bauab, Marlus Chorilli. Exploiting drug delivery systems for oral route in the peptic ulcer disease treatment. Journal of Drug Targeting 2021; 29(10): 1029 doi: 10.1080/1061186X.2021.1904249
|
| 58 |
Kiera Murphy, R. Paul Ross, C. Anthony Ryan, Eugene M. Dempsey, Catherine Stanton. Probiotics, Prebiotics, and Synbiotics for the Prevention of Necrotizing Enterocolitis. Frontiers in Nutrition 2021; 8 doi: 10.3389/fnut.2021.667188
|
| 59 |
Laura Mihaela Trandafir, Otilia Elena Frăsinariu, Elena Țarcă, Lăcrămioara Ionela Butnariu, Maria Magdalena Leon Constantin, Mihaela Moscalu, Oana Raluca Temneanu, Alina Sinziana Melinte Popescu, Marian George Melinte Popescu, Iuliana Magdalena Stârcea, Elena Cojocaru, Stefana Maria Moisa. Can Bioactive Food Substances Contribute to Cystic Fibrosis-Related Cardiovascular Disease Prevention?. Nutrients 2023; 15(2): 314 doi: 10.3390/nu15020314
|
| 60 |
Sofia D. Forssten, Arthur C. Ouwehand. Comprehensive Gut Microbiota. 2022; : 69 doi: 10.1016/B978-0-12-819265-8.00059-0
|
| 61 |
Yohannes T Ghebre. Proton Pump Inhibitors and Risk of Infection: Is Suppression of Immune Defence Molecules to Blame?. US Respiratory & Pulmonary Diseases 2021; 6(1): 3 doi: 10.17925/USPRD.2021.6.1.3
|
| 62 |
Manon Cairat, Marie Al Rahmoun, Marc J. Gunter, Gianluca Severi, Laure Dossus, Agnès Fournier. Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women. Breast Cancer Research 2020; 22(1) doi: 10.1186/s13058-020-01343-1
|
| 63 |
Cunye Yan, Yue Chen, Chenyu Sun, Mubashir Ayaz Ahmed, Chandur Bhan, Zhichun Guo, Hongru Yang, Yijing Zuo, Yue Yan, Lei Hu, Yiceng Sun, Yao Li, Qin Zhou. Does Proton Pump Inhibitor Use Lead to a Higher Risk of Coronavirus Disease 2019 Infection and Progression to Severe Disease? a Meta-analysis. Japanese Journal of Infectious Diseases 2022; 75(1): 10 doi: 10.7883/yoken.JJID.2021.074
|
| 64 |
Emelie C. Rotbain, Max J. Gordon, Noomi Vainer, Henrik Frederiksen, Henrik Hjalgrim, Alexey V. Danilov, Carsten U. Niemann. The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. Blood Advances 2022; 6(8): 2701 doi: 10.1182/bloodadvances.2021005716
|
| 65 |
Dibya L. Praharaj, Anil C. Anand. Nutrition in Viral Hepatitis. Current Hepatology Reports 2023; doi: 10.1007/s11901-023-00596-6
|
| 66 |
Andreas Thalheimer. Chirurgische Behandlung der Refluxkrankheit. Im OP 2021; 11(03): 105 doi: 10.1055/a-1220-4293
|
| 67 |
Andrea Nuzzo, James R. Brown. The Microbiome Factor in Drug Discovery and Development. Chemical Research in Toxicology 2020; 33(1): 119 doi: 10.1021/acs.chemrestox.9b00333
|
| 68 |
Piotr Dziechciarz, Katarzyna Krenke, Hania Szajewska, Andrea Horvath.
Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial. Pediatric Gastroenterology, Hepatology & Nutrition 2020; 23(3): 251 doi: 10.5223/pghn.2020.23.3.251
|
| 69 |
Yasutoshi Shiratori, Takashi Ikeya, Naoki Ishii, Kazuki Yamamoto, Tetsuro Honda, Kenkei Hasatani, Naohiro Yoshida, Tsutomu Nishida, Tetsuya Sumiyoshi, Shu Kiyotoki, Masahiro Arai, Ryota Niikura. Association between the chronic use of gastric acid suppressants and high‐risk colorectal polyps. JGH Open 2021; 5(3): 371 doi: 10.1002/jgh3.12503
|
| 70 |
Bhavneet K. Chawla, Robert E. Cohen, Elizabeth M. Stellrecht, Lisa M. Yerke. The influence of proton pump inhibitors on tissue attachment around teeth and dental implants: A scoping review. Clinical and Experimental Dental Research 2022; 8(5): 1045 doi: 10.1002/cre2.616
|
| 71 |
Mauro Giuffrè, Michele Campigotto, Giuseppina Campisciano, Manola Comar, Lory Saveria Crocè. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. American Journal of Physiology-Gastrointestinal and Liver Physiology 2020; 318(5): G889 doi: 10.1152/ajpgi.00161.2019
|
| 72 |
Kazuki Takada, Sebastiano Buti, Melissa Bersanelli, Mototsugu Shimokawa, Shinkichi Takamori, Taichi Matsubara, Tomoyoshi Takenaka, Tatsuro Okamoto, Motoharu Hamatake, Yuko Tsuchiya-Kawano, Kohei Otsubo, Yoichi Nakanishi, Isamu Okamoto, David J. Pinato, Alessio Cortellini, Tomoharu Yoshizumi. Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. European Journal of Cancer 2022; 172: 199 doi: 10.1016/j.ejca.2022.06.002
|
| 73 |
Bihan Li, Liping Rao. Pump proton inhibitors display anti‐tumour potential in glioma. Cell Proliferation 2022; doi: 10.1111/cpr.13321
|
| 74 |
Fang Lu, Yurong Ma, Hui Huang, Yue Zhang, Hui Kong, Yan Zhao, Huihua Qu, Qingguo Wang, Yang Liu, Zhenhui Kang. Edible and highly biocompatible nanodots from natural plants for the treatment of stress gastric ulcers. Nanoscale 2021; 13(14): 6809 doi: 10.1039/D1NR01099A
|
| 75 |
Amr Mohamed, Sylvia L. Asa, Thomas McCormick, Hilmi Al-Shakhshir, Arvind Dasari, Retuerto Mauricio, Iman Salem, Lee M. Ocuin, David Bajor, Richard T. Lee, J. Eva Selfridge, Arash Kardan, Zhenghong Lee, Norbert Avril, Shelby Kopp, Jordan M. Winter, Jeffrey M. Hardacre, John B. Ammori, Mahmoud A. Ghannoum. The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). Current Issues in Molecular Biology 2022; 44(5): 2015 doi: 10.3390/cimb44050136
|
| 76 |
Marzena Jabczyk, Justyna Nowak, Bartosz Hudzik, Barbara Zubelewicz-Szkodzińska. Microbiota and Its Impact on the Immune System in COVID-19—A Narrative Review. Journal of Clinical Medicine 2021; 10(19): 4537 doi: 10.3390/jcm10194537
|
| 77 |
Nele Brusselaers, Omid Sadr-Azodi, Lars Engstrand. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. Journal of Gastroenterology 2020; 55(4): 453 doi: 10.1007/s00535-019-01652-z
|
| 78 |
Xiao Wei, Jun Yu, Zhengkun Xu, Chun Wang, Yonggui Wu. Incidence, Pathogenesis, and Management of Proton Pump Inhibitor-Induced Nephrotoxicity. Drug Safety 2022; 45(7): 703 doi: 10.1007/s40264-022-01181-4
|
| 79 |
Thiruvinvamalai S. Dharmarajan. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing. Journal of the American Medical Directors Association 2021; 22(1): 15 doi: 10.1016/j.jamda.2020.09.046
|
| 80 |
Alexander J Friedman, Anna J Elseth, Joel R Brockmeyer. Proton Pump Inhibitors, Associated Complications, and Alternative Therapies: A Shifting Risk Benefit Ratio. The American Surgeon 2022; 88(1): 20 doi: 10.1177/0003134821991988
|
| 81 |
Camilla Virili, Giovanni Bruno, Maria Giulia Santaguida, Lucilla Gargano, Ilaria Stramazzo, Corrado De Vito, Alessia Cicenia, Giulia Scalese, Barbara Porowska, Carola Severi, Marco Centanni. Levothyroxine treatment and gastric juice pH in humans: the proof of concept. Endocrine 2022; 77(1): 102 doi: 10.1007/s12020-022-03056-1
|
| 82 |
Shingo Takashima, Fumio Tanaka, Yunosuke Kawaguchi, Yuki Usui, Kosuke Fujimoto, Yuji Nadatani, Koji Otani, Shuhei Hosomi, Yasuaki Nagami, Noriko Kamata, Koichi Taira, Tetsuya Tanigawa, Toshio Watanabe, Seiya Imoto, Satoshi Uematsu, Yasuhiro Fujiwara. Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice. Neurogastroenterology & Motility 2020; 32(7) doi: 10.1111/nmo.13841
|
| 83 |
Andrew F. Nyein, Shahla Bari, Stephanie Hogue, Yayi Zhao, Bradley Maller, Sybil Sha, Maria F. Gomez, Dana E. Rollison, Lary A. Robinson. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09210-2
|
| 84 |
Li-Qi Mao, Yan-Lin Zhou, Shuang-Shuang Wang, Lin Chen, Yue Hu, Lei-Min Yu, Jing-Ming Xu, Bin Lyu. Impact of Helicobacter pylori eradication on the gastric microbiome. Gut Pathogens 2021; 13(1) doi: 10.1186/s13099-021-00460-2
|
| 85 |
Alessandro Rizzo, Antonio Cusmai, Francesco Giovannelli, Silvana Acquafredda, Lucia Rinaldi, Andrea Misino, Elisabetta Sara Montagna, Valentina Ungaro, Mariagrazia Lorusso, Gennaro Palmiotti. Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Cancers 2022; 14(6): 1404 doi: 10.3390/cancers14061404
|
| 86 |
Heidi Cecilie Villmones, Adrian Halland, Tore Stenstad, Elling Ulvestad, Harald Weedon-Fekjær, Øyvind Kommedal. The cultivable microbiota of the human distal ileum. Clinical Microbiology and Infection 2021; 27(6): 912.e7 doi: 10.1016/j.cmi.2020.08.021
|
| 87 |
Soo Hee Jeong, Lara Molloy, Edmond Ang, Nuala Helsby. Re-thinking the possible interaction between proton pump inhibitors and capecitabine. Cancer Chemotherapy and Pharmacology 2022; 90(5): 381 doi: 10.1007/s00280-022-04473-9
|
| 88 |
Aws Hasan, Laith K. Hasan, Bernd Schnabl, Madeline Greytak, Rena Yadlapati. Microbiome of the Aerodigestive Tract in Health and Esophageal Disease. Digestive Diseases and Sciences 2021; 66(1): 12 doi: 10.1007/s10620-020-06720-6
|
| 89 |
Heloisa B. Assalin, Kelly Cristiane Gabriel De Almeida, Dioze Guadagnini, Andrey Santos, Caio J. Teixeira, Silvana Bordin, Guilherme Z. Rocha, Mario J. A. Saad. Proton Pump Inhibitor Pantoprazole Modulates Intestinal Microbiota and Induces TLR4 Signaling and Fibrosis in Mouse Liver. International Journal of Molecular Sciences 2022; 23(22): 13766 doi: 10.3390/ijms232213766
|